179 related articles for article (PubMed ID: 26632462)
1. [Combination antifungal therapy for invasive fungal disease in children with hematologic disease].
Qiu K; Deng L; Huang K; Guo H; Fang J; Xu H; Xue H; Li Y; Chen C; Zhou D
Zhonghua Xue Ye Xue Za Zhi; 2015 Nov; 36(11):912-7. PubMed ID: 26632462
[TBL] [Abstract][Full Text] [Related]
2. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.
Qiu KY; Liao XY; Fang JP; Xu HG; Li Y; Huang K; Zhou DH
Transpl Infect Dis; 2019 Jun; 21(3):e13066. PubMed ID: 30859662
[TBL] [Abstract][Full Text] [Related]
3. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.
Blyth CC; Hale K; Palasanthiran P; O'Brien T; Bennett MH
Cochrane Database Syst Rev; 2010 Feb; 2010(2):CD006343. PubMed ID: 20166083
[TBL] [Abstract][Full Text] [Related]
4. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
5. EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients.
Llinares P; Ruiz I; Zaragoza R; Ferrer R; Rodríguez AH; Maseda E; Grau S;
Rev Iberoam Micol; 2016; 33(4):206-215. PubMed ID: 27751781
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.
Groll AH; Silling G; Young C; Schwerdtfeger R; Ostermann H; Heinz WJ; Gerss J; Kolve H; Lanvers-Kaminsky C; Vieira Pinheiro JP; Gammelin S; Cornely OA; Wuerthwein G
Antimicrob Agents Chemother; 2010 Oct; 54(10):4143-9. PubMed ID: 20660670
[TBL] [Abstract][Full Text] [Related]
7. [Drug interactions in critically-ill patients. An important factor in the use of micafungin?].
Garnacho-Montero J; Jiménez Parrilla F
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():33-7. PubMed ID: 21420575
[TBL] [Abstract][Full Text] [Related]
8. [Potential of anidulafungin in combined therapy].
Gadea I; Mensa J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():51-5. PubMed ID: 19572435
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
[TBL] [Abstract][Full Text] [Related]
10. Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections.
Nivoix Y; Zamfir A; Lutun P; Kara F; Remy V; Lioure B; Rigolot JC; Entz-Werlé N; Letscher-Bru V; Waller J; Levêque D; Koffel JC; Beretz L; Herbrecht R
J Infect; 2006 Jan; 52(1):67-74. PubMed ID: 16368463
[TBL] [Abstract][Full Text] [Related]
11. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
12. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.
Yilmaz D; Balkan C; Ay Y; Akin M; Karapinar B; Kavakli K
Mycoses; 2011 May; 54(3):234-42. PubMed ID: 19906090
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and Safety of Low-dose Amphotericin B in Different Antifungal Strategies for Treatment of Invasive Fungal Disease in Patients with Hematological Malignancies].
Yang L; Jin XS; Li JH; Liu J; Guan W; Gao HH; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):221-225. PubMed ID: 28245405
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study of amphotericin B in the treatment of invasive fungal infection in 111 hematological disorder patients with neutrocytopenia].
Tong HY; Zhang FJ; Xiao F; Qian WB; Meng HT; Mai WY; Tong Y; Mao LP; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):472-5. PubMed ID: 19035181
[TBL] [Abstract][Full Text] [Related]
15. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
Ellis M; Frampton C; Joseph J; Alizadeh H; Kristensen J; Hauggaard A; Shammas F
J Med Microbiol; 2006 Oct; 55(Pt 10):1357-1365. PubMed ID: 17005784
[TBL] [Abstract][Full Text] [Related]
16. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
17. [The clinical study of invasive fungal infection in 76 cases of hematologic diseases].
Wu FF; Sun H; Gan SL; Ma J; Liu YF; Xie XS; Sun L; Liu LX; Wan DM
Zhonghua Nei Ke Za Zhi; 2013 Mar; 52(3):218-20. PubMed ID: 23856113
[TBL] [Abstract][Full Text] [Related]
18. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
19. Combination antifungal therapy: where are we now, and where are we going?
Marr K
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):24-9. PubMed ID: 15651179
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B.
Cornely OA; Maertens J; Bresnik M; Ullmann AJ; Ebrahimi R; Herbrecht R
J Antimicrob Chemother; 2010 Jan; 65(1):114-7. PubMed ID: 19887460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]